Research
Hormonal
GLP-1R signaling primarily occurs through the Gαs/cAMP pathway, leading to insulin secretion, but also involves Gαq and β-arrestin pathways which contribute to receptor internalization and other metabolic effects.
GLP-1 drugs work by activating specific pathways in the body. The main pathway increases insulin when blood sugar is high. Other pathways help with receptor recycling and may contribute to other effects like cell survival.
GoodQualifiesHIGH confidence
Currently, it is believed that GLP-1R predominantly signals through the Gαs/cAMP pathway; however, there is evidence that GLP-1R couples with Gαq and other G proteins... The Gαs/cAMP pathway directly leads to the glucose-induced secretion of insulin granules.
Why this rating
Based on structural and functional studies of the receptor.
Source
GLP-1R Signaling and Functional Molecules in Incretin Therapy
Wenwei Wan et al. · Molecules · 2023
DOI 10.3390/molecules28020751
narrative_reviewCited 37×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- GLP-1 receptor agonists improve glycemic control and promote weight loss in type 2 diabetes and obesity by stimulating glucose-dependent insulin secretion and reducing appetite, with efficacy superior to many existing therapies.Strong
- Multi-agonists targeting GLP-1R along with other receptors (GIPR, GCGR) demonstrate superior weight loss and glycemic control compared to single GLP-1R agonists.Strong
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →